Dai W S, LaBraico J M, Stern R S
Department of Drug Safety, Hoffmann-La Roche Inc., Nutley, NJ 07110.
J Am Acad Dermatol. 1992 Apr;26(4):599-606. doi: 10.1016/0190-9622(92)70088-w.
Exposure to isotretinoin during pregnancy is associated with a high risk of major fetal malformations.
Our purpose was to determine the reasons for and outcomes of in utero isotretinoin exposure.
On the basis of 433 spontaneous reports, we describe the likely reasons these exposures occurred and the outcomes of these pregnancies. In our analysis of the outcomes of pregnancy, we separately consider the pregnancies known to us before their outcomes were determined as prospective cases.
Timing of conception in relation to initiation of therapy with isotretinoin was known for 396 women. Of these, 130 patients (33%) were already pregnant when they started isotretinoin. An additional 65 patients (16%) became pregnant in the first 3 weeks of isotretinoin use. Pregnancy outcomes were known on 409 pregnancies. Among these, 222 (54%) ended in elective abortion and 29 (7%) in spontaneous or missed abortion. Of 151 births, 72 (48%) were normal, 71 (47%) had congenital malformations, and 8 (5%) had abnormalities other than malformations. Of 94 prospectively ascertained pregnancies that ended in births, 28% had congenital malformations (95% confidence interval 19% to 37%). Exposure to isotretinoin during any time and for as little as one capsule within the first trimester have been associated with congenital malformations.
The high proportion of exposures in already or recently pregnant women illustrates the importance of obtaining a negative pregnancy test before the initiation of isotretinoin therapy and of delaying the commencement of isotretinoin therapy until the onset of the next menstrual period. Furthermore, the importance of reliable contraceptive methods should be emphasized to patients when isotretinoin is prescribed. Young women seem to be at an especially high risk of pregnancy exposure to isotretinoin. There is a substantial risk of congenital malformation at all therapeutic doses of isotretinoin, even when the duration of exposure is brief.
孕期接触异维A酸与胎儿发生严重畸形的高风险相关。
我们的目的是确定子宫内接触异维A酸的原因及后果。
基于433份自发报告,我们描述了这些接触发生的可能原因以及这些妊娠的结局。在分析妊娠结局时,我们将结局确定前已知的妊娠单独视为前瞻性病例。
396名女性的受孕时间与开始使用异维A酸治疗的时间关系已知。其中,130名患者(33%)开始使用异维A酸时已怀孕。另外65名患者(16%)在使用异维A酸的前3周内怀孕。409次妊娠的结局已知。其中,222次(54%)以选择性流产告终,29次(7%)以自然流产或稽留流产告终。在151例分娩中,72例(48%)正常,71例(47%)有先天性畸形,8例(5%)有畸形以外的异常。在94例前瞻性确定的分娩结局的妊娠中,28%有先天性畸形(95%置信区间19%至37%)。在孕早期的任何时间接触异维A酸,即使仅接触一粒胶囊,都与先天性畸形有关。
已怀孕或近期怀孕的女性中接触异维A酸的比例很高,这说明了在开始异维A酸治疗前进行阴性妊娠试验以及将异维A酸治疗的开始推迟到下次月经来潮的重要性。此外,在开具异维A酸处方时,应向患者强调可靠避孕方法的重要性。年轻女性似乎尤其容易在孕期接触异维A酸。异维A酸的所有治疗剂量都存在先天性畸形的重大风险,即使接触时间短暂。